In January this year, the FDA updated the EUA to limit use of REGEN-COV in the US due to omicron variant. Credit: svetjekolem on Unsplash.

The US Food and Drug Administration (FDA) has extended its review of Regeneron Pharmaceuticals’ Biologics License Application (BLA) for REGEN-COV for Covid-19 by three months.

REGEN-COV is a combination of two monoclonal antibodies, casirivimab and imdevimab.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Invented by Regeneron, the antibody cocktail leverages VelocImmune and VelociSuite technologies and can potentially hinder the SARS-CoV-2 virus’ infectivity. 

The company is partnering with Roche, which is in charge of the development and supply of REGEN-COV outside the US as Ronapreve. 

The latest development is a result of ongoing talks with the FDA about the pre-exposure prophylactic usage, for which Regeneron had presented further data from its concluded prophylaxis trial.

Regeneron noted that the regulatory agency had accepted the data for review earlier. 

The FDA recognised the latest submission of further data as a key amendment to the BLA and has given an updated target action date of 13 July this year. 

No additional studies were sought by the FDA to conclude the review of the BLA.

In November 2020, the US Food and Drug Administration (FDA) granted Emergency Use Authorisation (EUA) for the antibody cocktail to treat patients with mild to moderate Covid-19.

It was also indicated as a prophylaxis for Covid-19 in certain people. 

The regulatory agency updated EUA in January this year to limit the usage of REGEN-COV in certain geographic regions.

The move came after data showed that the antibody cocktail was unlikely to be active against the Omicron variant of the SARS-CoV-2 virus.

At present, REGEN-COV is not authorised for usage in any states, territories or jurisdictions in the US. 

Meanwhile, the company is advancing its next-generation antibodies and has commenced a first-in-human clinical trial.